This collection of content is organized and funded by Novartis Pharma AG.
This collection of content, including a series of six videos, is derived from a recent Novartis sponsored satellite symposium at EURETINA Paris 2019 around innovations in retinal gene therapy. Three leading experts, José Alain Sahel, MD; Bart P. Leroy, MD, PhD; and Mark Pennesi, MD, PhD, offer insights for understanding the patient experience and patient selection, review recent innovations in retinal gene therapy for RPE65 mutations, and discuss implementing retinal gene therapy in clinical practice in relation to treatment with voretigene neparvovec.
In an upcoming issue of Retina Today, there will also be an interactive supplement, so please return for more exciting content from this symposium.
José Alain Sahel, MD
Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts, Paris, France
University of Pittsburgh Medical School, Pittsburgh, PA
Bart P. Leroy, MD, PhD
Ghent University and Ghent University Hospital, Ghent, Belgium
Children’s Hospital of Philadelphia, Philadelphia, PA
Mark Pennesi, MD, PhD
Casey Eye Institute, Oregon Health & Science University, Portland OR